Percutaneous transplantation of skeletal myoblast in the treatment of post-infarction injury

Tomasz Siminiak; Emanuele Meliga; Olga Jerzykowska; Patrick W. Serruys

doi:10.1093/eurheartj/sul064

Percutaneous transplantation of skeletal myoblast in the treatment of post-infarction injury

Tomasz Siminiak, Emanuele Meliga, Olga Jerzykowska, Patrick W. Serruys

Research output: Contribution to a Journal (Peer & Non Peer) › Review article › peer-review

2 Citations (Scopus)

Abstract

Cell therapy may be a potentially attractive approach to restore myocardial contractile performance after an infarction injury. Multipotent stem cells are currently being studied as a possible cell source for myocardial repair within the first few days after the infarction onset in non-revascularizable areas of the left ventricle having viable myocardium. In the presence of fibrotic post-infarction scar with no detectable myocardial viability, direct myocyte precursors, i.e. myoblasts, are being considered as a potential source of new muscle fibres. We review the current clinical experience with transplantation of the autologous skeletal myoblasts in patients with post-infarction heart failure, focusing on percutaneous cell transplantations performed as a sole procedure.

Original language	English
Pages (from-to)	H57-H64
Journal	European Heart Journal, Supplement
Volume	8
Issue number	H
DOIs	https://doi.org/10.1093/eurheartj/sul064
Publication status	Published - Dec 2006
Externally published	Yes

Keywords

Catheter systems
Cell transplantation
Heart failure
Myoblasts

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/eurheartj/sul064

Cite this

@article{0627d5a347ef476888fa6836266bf5b6,

title = "Percutaneous transplantation of skeletal myoblast in the treatment of post-infarction injury",

abstract = "Cell therapy may be a potentially attractive approach to restore myocardial contractile performance after an infarction injury. Multipotent stem cells are currently being studied as a possible cell source for myocardial repair within the first few days after the infarction onset in non-revascularizable areas of the left ventricle having viable myocardium. In the presence of fibrotic post-infarction scar with no detectable myocardial viability, direct myocyte precursors, i.e. myoblasts, are being considered as a potential source of new muscle fibres. We review the current clinical experience with transplantation of the autologous skeletal myoblasts in patients with post-infarction heart failure, focusing on percutaneous cell transplantations performed as a sole procedure.",

keywords = "Catheter systems, Cell transplantation, Heart failure, Myoblasts",

author = "Tomasz Siminiak and Emanuele Meliga and Olga Jerzykowska and Serruys, {Patrick W.}",

year = "2006",

month = dec,

doi = "10.1093/eurheartj/sul064",

language = "English",

volume = "8",

pages = "H57--H64",

journal = "European Heart Journal, Supplement",

issn = "1520-765X",

number = "H",

}

TY - JOUR

T1 - Percutaneous transplantation of skeletal myoblast in the treatment of post-infarction injury

AU - Siminiak, Tomasz

AU - Meliga, Emanuele

AU - Jerzykowska, Olga

AU - Serruys, Patrick W.

PY - 2006/12

Y1 - 2006/12

N2 - Cell therapy may be a potentially attractive approach to restore myocardial contractile performance after an infarction injury. Multipotent stem cells are currently being studied as a possible cell source for myocardial repair within the first few days after the infarction onset in non-revascularizable areas of the left ventricle having viable myocardium. In the presence of fibrotic post-infarction scar with no detectable myocardial viability, direct myocyte precursors, i.e. myoblasts, are being considered as a potential source of new muscle fibres. We review the current clinical experience with transplantation of the autologous skeletal myoblasts in patients with post-infarction heart failure, focusing on percutaneous cell transplantations performed as a sole procedure.

AB - Cell therapy may be a potentially attractive approach to restore myocardial contractile performance after an infarction injury. Multipotent stem cells are currently being studied as a possible cell source for myocardial repair within the first few days after the infarction onset in non-revascularizable areas of the left ventricle having viable myocardium. In the presence of fibrotic post-infarction scar with no detectable myocardial viability, direct myocyte precursors, i.e. myoblasts, are being considered as a potential source of new muscle fibres. We review the current clinical experience with transplantation of the autologous skeletal myoblasts in patients with post-infarction heart failure, focusing on percutaneous cell transplantations performed as a sole procedure.

KW - Catheter systems

KW - Cell transplantation

KW - Heart failure

KW - Myoblasts

UR - http://www.scopus.com/inward/record.url?scp=33845990259&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/sul064

DO - 10.1093/eurheartj/sul064

M3 - Review article

AN - SCOPUS:33845990259

SN - 1520-765X

VL - 8

SP - H57-H64

JO - European Heart Journal, Supplement

JF - European Heart Journal, Supplement

IS - H

ER -

Percutaneous transplantation of skeletal myoblast in the treatment of post-infarction injury

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this